Fidelity Investments’s Compass Therapeutics CMPX Stock Holding History
Bought
Maintained
Sold
Other funds holding CMPX
TCM
O
SCM
ES
VC
PAI
Fidelity Investments's CMPX Position: Q2 2026 in Review
Fidelity Investments reduced its Compass Therapeutics (CMPX) stake by 33% in Q2 2026, selling an estimated $1.74M and leaving 1,212,196 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2655.
Fidelity Investments first reported a position in CMPX in Q4 2021 and has held it in 19 quarters since. The position peaked at $32M in Q4 2022. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.
- Fidelity Investments held 1,212,196 shares of Compass Therapeutics worth $2.65M as of Q2 2026.
- Fidelity Investments sold 589,525 Compass Therapeutics shares in Q2 2026, an estimated $1.74M.
- Compass Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2655 holding.
- Fidelity Investments first reported a position in Compass Therapeutics in Q4 2021 and has held it in 19 quarters since.
- Fidelity Investments's Compass Therapeutics position peaked at $32M in Q4 2022.
- 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.
Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.